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Abstract: The trade-offs between survival benefits and therapeutic adverse effects
on quality of life (QOL) is always an important clinical issue for cancer and AIDS
patients. The International Breast Cancer Study Group (IBCSG) conducted a large
clinical trial, IBCSG Trial VI, to examine the duration and timing of adjuvant ther-
apy for advanced breast cancer patients after the initial removal surgery. We present
a novel joint model for longitudinal and survival data to evaluate the relationship
between QOL and breast cancer progression, and also assess issues associated with
different therapeutic procedures and baseline covariates. Multidimensional longi-
tudinal QOL measurements are modeled in a hierarchical mixed effects model to
account for psychological fluctuations and measurement errors, provide estimates
for time points where QOL data are not available, and to explicitly allow for direct
inferences about different dependence structures in the QOL data over time and
over different QOL measures (indicators). A parametric survival model is also pro-
posed for disease-free survival (DFS) to incorporate the underlying smooth QOL
trajectories and prognostic factors. This survival model is attractive and capable
of accommodating both zero and nonzero cure fractions. With advances in modern
medicine, a positive cure fraction is often tenable for breast cancer patients since
many are completely cured after surgery, and are no longer susceptible to relapse.
A Bayesian paradigm is adopted to facilitate the estimation process and ease the
computational complexity.
Key words and phrases: Breast cancer clinical trial, Cure rate model, random
effects.
1. Introduction
In cancer and AIDS clinical trials, it is becoming increasingly common to re-
peatedly collect one or more biologic markers during the follow-up for the primary
endpoint, the time to an event. These longitudinal markers are often important
indicators for disease progression, but are prone to measurement error and ran-
dom fluctuations, and thus their direct use as time-varying covariates in a survival
model is inappropriate (see Ibrahim, Chen and Sinha (2001, Chap.7)). Jointly
modeling the longitudinal markers and survival data provides a way to account
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for errors in the longitudinal measurements, and allows the presence of treat-
ment and baseline covariates, unbalanced observations of biomarkers over time,
and censoring information associated with survival time. The model building
often starts from models for the longitudinal component and then characteris-
tics of the longitudinal model are incorporated into the model for the survival
component. Both Frequentist and Bayesian approaches have been examined in
the literature. Tsiatis and Davidian (2004) and Ibrahim, Chen and Sinha (2001,
Chap.7) provide a detailed discussion of joint modeling.
The model proposed here was primarily motivated by a clinical trial con-
ducted by the International Breast Cancer Study Group (IBCSG). IBCSG di-
rected a large clinical trial, IBCSG Trial VI, in premenopausal women with node-
positive breast cancer to examine the efficacy of post-surgery chemotherapy pro-
cedures. The therapeutic procedure is hypothesized to affect breast cancer pro-
gression, monitored in terms of disease free survival (DFS) which corresponds to
time to breast cancer relapse, through two paths, either directly or indirectly with
an intermediate time-dependent factor, patients’ quality of life (QOL). The toxi-
city of a therapeutic procedure may adversely affect a patient’s QOL and QOL is
typically associated with DFS. A joint modeling framework for longitudinal and
survival data not only allows investigation for both paths, but accommodates all
important data features and complications associated with them. Particularly in
response to the characteristics of the IBCSG data, a new Bayesian joint modeling
with a multivariate extension for the longitudinal component and the possible
presence of cure for the survival component DFS, is therefore proposed.
In the IBCSG trial, four distinct QOL indicators were assessed repeatedly
over time with a self-reported QOL questionnaire. A multivariate longitudinal
model is required to incorporate treatment and baseline covariates, and account
for psychological fluctuations, measurement errors and unbalanced observations.
Ibrahim, Chen and Sinha (2004), Xu and Zeger (2001) and Song, Davidian and
Tsiatis (2002) have proposed various types of joint models with a multivariate
longitudinal component. Here, we present a hierarchical mixed effects model to
explicitly allow for direct inferences about different dependence structures in the
QOL data over time as well as over different indicators.
Due to advances in cancer research, particularly breast cancer, a significant
proportion of patients after the initial surgery are not susceptible to cancer re-
lapse, that is, they are “cured” of the disease. Figure 1 shows the Kaplan-Meier
curves for DFS for all patients. A plateau appears to occur in the survival curve
after approximately 10 years of follow-up, hence suggesting a possible cure frac-
tion in the population. Joint longitudinal-survival-cure models have been inves-
tigated by several authors (see Brown and Ibrahim (2003), Law, Taylor and San-
dler (2002) and Yu, Law, Taylor and Sandler (2004)). The joint model we pro-
pose here is quite different from what has been proposed in the literature. First
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and foremost, the proposed survival model does not impose a boundary value on
the parameter space, as is the case for the classic mixture (Berkson and Gage
(1952)) and non-mixture cure models (Yakovlev and Tsodikov (1996)). The in-
corporation of longitudinal QOL assessments in the survival model helps de-
termine the proportion of cured and non-cured patients in the trial, and hence
allows the flexibility for either zero or nonzero cure fractions in the joint model.
In addition, our survival model maintains a proportional hazards structure when
only baseline covariates are considered in the model. The rest of the article is
organized as follows. In Section 2, we describe the basic data structure from the
breast cancer clinical trial. In Section 3, we review the basic setup and demon-
strate some attractive properties of our model. We examine the performance and
robustness of our proposed model with a set of simulation studies in Section 4,
and then apply the model to the analysis of the IBCSG dataset in Section 5. A
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Figure 1. Superimposed survival curves.
2. The Data Structure
The IBCSG conducted a clinical trial, IBCSG Trial VI, in premenopausal
women with node-positive breast cancer to investigate both the duration of
adjuvant chemotherapy (three vs six initial cycles of oral cyclophosphamide,
methotrexate, and fluorouracil (CMF)) and the reintroduction of three single
courses of delayed chemotherapy. Each participant was randomly assigned in a
2 × 2 factorial design to receive either six initial courses of CMF at consecutive
months 1 to 6 with (CMF6RE) or without (CMF6) three single courses of rein-
troduction CMF given on month 9, 12 and 15; or three initial courses of CMF
at consecutive months 1 to 3 with (CMF3RE) or without (CMF3) three single
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courses of reintroduction CMF given on month 6, 9 and 12. Randomization was
stratified according to participation institution, type of surgery, and estrogen re-
ceptor (ER) status. Date of relapse is defined as the time when recurrent disease
is diagnosed or first suspected, and disease-free survival (DFS) is defined as the
time from randomization to any relapse, occurrence of a second primary cancer,
or death. Different therapeutic procedures may directly affect DFS, as well as
age, ER status (negative/positive), and number of positive nodes of the tumor.
The trial is described in greater detail by the International Breast Cancer Study
Group (1996).
As part of the trial, the QOL questionnaire was assigned periodically to
all participants and included four indicators of health-related QOL that are es-
pecially relevant to breast cancer patients. Physical well-being (lousy—good),
mood (miserable—happy), appetite (none—good) and perceived coping (”How
much effort does it cost you to cope with your illness?” (a great deal—none))
were assessed with single-item linear analogue self-assessment scales. The scores
were scaled between 0 to 100 with a larger number indicating a better perceived
QOL. Measurement errors may occur by possible imperfect reliability of the ques-
tionnaire and are assumed to take place independently over time. Different QOL
indicators may be related to each other and the correlation is most likely to be
positive. For example, a happy mood mostly goes with a good appetite and
physical well-being, and vice versa. These QOL measurements were important
in the investigation of breast cancer progression since the toxicity of adjuvant
chemotherapy may have adverse effects on patients’ QOL, and hence associate
with DFS. The incorporation of longitudinal QOL measures in the model of DFS
allows for the evaluation of the indirect therapeutic effects through the interme-
diate QOL factor. In addition, the direct therapeutic effects for optimal duration
and timing of adjuvant therapy can also be examined. Both patients and physi-
cians can make their decisions about therapies after balancing the trade-offs
between survival benefits and QOL pay-offs.
We analyzed data from 831 patients from Switzerland, Sweden and New
Zealand/Australia, each with more than one complete set of QOL assessments
over time. The perceptions of QOL were assessed at the start of the study and
at months 3 and 18 after randomization. A total of 2,152 QOL observations
are included in the dataset. Figure 2 displays median QOL scores at three ob-
servational times. On average, patients perceive improvement in their QOL 18
months after the initial surgery, and the improvement is most substantial for
their mood and perceived coping. However, the perceived mood and coping are
relatively worse than perceived appetite and physical well-being over time. The
median DFS is 7.836 years for all patients, with a censoring rate of 51.62%. For
different therapeutic groups, the median DFS is 6.188 years for CMF3 therapy,
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6.045 years for CMF6 therapy, 8.033 years for CMF3RE therapy and 9.257 years
for CMF6RE therapy. The Kaplan-Meier curve for DFS in Figure 1 suggests a
nonzero cure fraction after a long follow-up. A joint model capable of accommo-
dating nonzero cure fractions for time-to-event data is essential for investigating
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Figure 2. Median QOL scores over time.
3. A New Class of Joint Models
In this section, we review the background and setup for our model. Let Y
be the possibly censored time-to-event, X be the observed vector of longitudinal
QOL measures, Z be the vector of baseline covariates for time-to-event and R
be the vector of covariates (possibly time-varying) for the longitudinal measures.
The components of Z may be different from the components of R, which there-
fore allows different covariate information in the model of time-to-event and the
longitudinal measures. With measurement errors and psychological fluctuations
corresponding to each QOL indicator, we let a latent trajectory function X∗ rep-
resent the underlying true QOL, and R affects X only through its influence on
X∗. In the framework of joint modeling, we specifically assume that the clinical
event time Y and vector of QOL measures X are conditionally independent given
X∗. Based upon these assumptions, we have
P (Y,X|Z,R) =
∫
P (Y |Z,X∗)P (X|X∗)P (X∗|R)dX∗. (3.1)
The joint likelihood of the complete data {Y,X,X∗} requires the specification of
three components, P (Y |Z,X∗), P (X|X∗) and P (X∗|R). In the literature, several
authors have proposed methods based on different distributional assumptions for
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these three components. Our assumptions for [X|X∗] and [X∗|R] result in a
multivariate longitudinal model with explicit dependence structures among the
repeated measures, and hence allow for direct inference about each structure. We
also propose a parametric survival model accommodating both zero and nonzero
cure fractions for [Y |Z,X∗].
3.1. The multivariate longitudinal process
With more than one QOL indicator measured over time, two levels of depen-
dence structures are involved in the observations of a single patient. The first
level involves dependence over time for each indicator, while the second level in-
volves dependence over different indicators. A multivariate mixed effects model
is proposed to explicitly model these two sources of dependence structures. Let
xik(tij) be an assessment of the kth QOL indicator for the ith patient at time tij
and x∗ik(tij) be the corresponding trajectory function representing its underlying
true value, where k = 1, . . . , q, j = 1, . . . , ni, and i = 1, . . . , n. The longitudinal
model for xik(tij) is given by
xik(tij) = x
∗
ik(tij) + ǫijk, (3.2)
where ǫijk represents the residual component consisting of both the psychological
fluctuation and measurement error. Let Rik(tij) be the vector of covariates
(possibly time-varying) for the kth QOL indicator at time tij . The trajectory
function is modeled as
x∗ik(tij) = Rik(tij)ηk + W ik(tij)bik, (3.3)
where W ik(tij) is the random effects design matrix and may be a subset of the
fixed effects design matrix Rik(tij), and ηk and bik are vectors of the correspond-
ing fixed and random effects parameters of length mk and υk, respectively. Let
ǫij· = [ǫij1, . . . , ǫijq]





ǫij· is independent of bik. The residuals of the longitudinal QOL indicators ob-
served at the same time may be correlated with each other due to psychological
fluctuation, but are assumed to be independent among observations assessed at
different time points. Due to the significant separation in time between obser-
vations, correlation (induced by psychological fluctuation) among residuals over
time is assumed to be negligible. Measurement errors are assumed to occur in-
dependently over time and over different QOL indicators. After some algebraic
derivations, the structure of Σ characterizes the association between QOL indi-
cators measured at the same time, and is assumed to be common across time
and patients. A common correlation structure among QOL indicators over time
is psychologically and biologically plausible. For instance, a better mood may
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relate to a better appetite, and the correlation is likely to be constant over time.
On the other hand, the introduction of the random effects bik in the trajectory
function induces a common factor for repeated QOL measures of the ith patient
at the kth indicator. The independence between bik’s over different QOL indica-
tors is tenable, since we assumed a distinct underlying mechanism in driving each
QOL dimension. The structure of Ψk describes the association between repeated
observations of the kth QOL indicator and is allowed to be distinct for different
indicators. In addition, QOL indicators measured at different time points are set
to be uncorrelated. An extensive set of simulations was conducted in Section 4
to assess the robustness of our joint model for these longitudinal assumptions,
such as independence and normal distribution of the random effects bik’s.
Xu and Zeger (2001) proposed a joint model to evaluate multiple surrogate
endpoints in a schizophrenia clinical trial. They assumed ǫijk ∼ N(0, σ
2
k) and
bi ∼ Nυ(0,Ψ) independently, where bi = [b
T
i1, . . . , b
T
iq]
T and υ = υ1 + · · · + υq.
The joint distributional assumption on the random effects bi simultaneously mod-
els the two dependence structures. The specification of Ψ alone carries all of the
information about dependence between the repeated measures, including corre-
lations between markers measured at different time points. With Xu and Zeger’s
model, making separate inferences about the different dependence structures be-
comes less straightforward. The difference between the number of covariance
parameters in their model and our model is (1/2)
∑q
k 6=k′=1 υkυk′ − q(q − 1)/2,
which increases with the dimension of the random effects and the number of
markers measured repeatedly over time. The two models are equivalent in the
case of a univariate longitudinal process.
3.2. The time-to-event model
Joint models with a survival component incorporating a nonzero cure fraction
have been established either by a two-component mixture (Law et al. (2002) and
Yu et al. (2004)) or a non-mixture (Brown and Ibrahim (2003)) approach. The
survival model we propose here is quite different from what has been presented
in the literature and, particularly, does not impose a boundary value on the
parameter space to require a nonzero cure fraction. Motivated by the promotion
time model (Yakovlev and Tsodikov (1996)), we propose a novel generalization
that allows for a zero as well as a nonzero cure fraction. We do this by specifying






λ(t)F̃ (y − t)dt
}
, (3.4)
where λ(t) is a non-negative function over time, and F̃ (t) is the distribution func-
tion of some non-negative random variable with F̃ (0) = 0. Aside from the statis-
tical properties of this survival function, described later in the section, this model
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may be derived from biological considerations characterizing tumor growth. In
the progression of cancer relapse, there exist clonogenic tumor cells (clonogens)
that are capable of producing a detectable tumor mass. These clonogens may
occur in clumps over time and, once they appear, are assumed to independently
develop into a detectable tumor mass. If any of the clonogens occur and fully
develop during the follow-up period, the patient would be observed to experience
a relapse, otherwise would be considered as a censored case. The statistical link
of this disease process to our survival function in (3.4) is through the assumptions
that the number of clonogens over time, N(t), follows a nonhomogeneous Pois-
son process with mean λ(t), and the time of a clonogen to become a detectable
tumor comes from the distribution function F̃ (t). This mechanism helps facili-
tate our estimation process and computational development. For instance, the
introduction of N∗, the total number of clonogens, makes it straightforward for
the specification of the joint likelihood in Section 3.3 and the construction of the
MCMC algorithm.












0 λ(t)F (y−t)dt is bounded as y → ∞, the survival function has a nonzero
cure fraction, otherwise the survival function in (3.4) leads to a proper survival
function (i.e. S(∞) = 0). Using the properties of a distribution function F̃ (t)

































0 λ(t)dt. In other words, a cure rate model is characterized by
a bounded cumulative risk, Λ(t), while a proper survival model is characterized
by an unbounded cumulative risk. Specific demonstrations about how a cure
fraction is governed by the longitudinal trajectories and their relationship with





λ(t)f̃(y − t)dt, (3.7)
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where f̃(y) = d
dy
F̃ (y). Equation (3.7) has the proportional hazards structure
when the baseline covariates are modeled through λ(t), and no time-varying
covariates are considered. The proposed survival function in (3.4) can also be
mathematically linked to the two-component mixture model. We can write (3.4)
as





0 λ(t)F̃ (y − t)dt} − exp{−Λ(y)}
1 − exp{−Λ(y)}
.
When the cure fraction is positive, exp{−Λ(y)} indicates the probability of cure,
and S1(y) represents the survival function for the “non-cured” group. We note
that S∗1(0) = 1 and S
∗
1(∞) = 0, so that S
∗
1(y) is a proper survival function.
To incorporate information from both the longitudinal trajectories x∗k(t), k =
1, . . . , q, and baseline covariates, Z, in our survival model, we let all covariates











Entering the covariates in this fashion corresponds to a canonical link in a Pois-
son generalized linear model, with N(t) being the Poisson count in the disease
process. All covariates may be assumed to affect survival biologically through
their impact on the mean number of clonogens over time. Specifically, a nega-
tive regression coefficient leads to a smaller hazard, whereas a positive coefficient
leads to a larger hazard, when the corresponding covariate takes a positive value.
As mentioned earlier, the limiting behavior of Λ(t) determines the property of our
survival function, and hence the trajectory functions x∗k(t), and the relationship
between the longitudinal trajectories and survival outcome, that is the γk’s, to-
gether account for the presence or absence of a cure fraction. For example, with
linear trajectories x∗k(t) = βk0 + βk1t for k = 1, . . . , q, the sign of
∑q
k=1 γkβk1
determines the limiting behavior of Λ(t) as well as the presence of a cure frac-
tion: negative
∑q
k=1 γkβk1 leads to a bounded Λ(t) and results in a positive cure
fraction, whereas a non-negative
∑q
k=1 γkβk1 leads to an unbounded Λ(t) and
results in a zero cure fraction. For positive βk1’s, when the coefficients of all the
γk’s are negative, Λ(t) is bounded and a positive cure fraction is obtained in the
model, with smaller coefficients corresponding to larger cure fractions. On the
other hand, when the coefficients of all the γk’s are positive, the model results
in an unbounded Λ(t) and a zero cure fraction. Furthermore, with quadratic
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trajectories x∗k(t) = βk0 + βk1t + βk2t
2 for k = 1, . . . , q, the sign of
∑q
k=1 γkβk2
determines the limiting behavior of Λ(t) and the presence of a cure fraction.
3.3 Joint likelihood and priors
In this subsection, we construct the joint likelihood with a specific choice of
the trajectory functions and distribution function F̃ (t). This setup is later used
in the analysis of the IBCSG data. Let X = {xik(tij), i = 1, . . . , n, j = 1, . . . , ni,
k = 1, . . . , q}, X∗ = {x∗ik(tij), i = 1, . . . , n, j = 1, . . . , ni, k = 1, . . . , q} and
R = (R1, . . . ,Rn), where xik(tij) and x
∗
ik(tij) are the respective observed and
true kth QOL indicator for the ith patient at time tij , and Ri is the corresponding
vector of baseline covariates for longitudinal QOL indicators. For each QOL
indicator, we consider a linear trajectory function over time as
x∗ik(tij) = Riηk + bik0 + bik1tij = τik0 + τik1tij,
where we hierarchically center (Gelfand, Sahu and Carlin (1996)) τik0 = Riηk +
bik0 and τik1 = bik1 to facilitate convergence of the MCMC algorithms. Let
τ 0 = (τ110, . . . , τnq0) and τ 1 = (τ111, . . . , τnq1). Further, let Y = (Y1, . . . , Yn),
ν = (ν1, . . . , νn), N
∗ = (N∗1 , . . . , N
∗
n) and Z = (Z1, . . . , Zn), where Yi is the ob-
served DFS for the ith patient, νi is the corresponding censoring indicator which
equals to 1 if Yi is a failure time and 0 if it is right censored, N
∗
i indicates the total
number of clonogens by the observed failure time for the ith patient as described
in Section 3.2, and Zi represents the corresponding vector of baseline covari-
ates for DFS. The observed data is then given by Dobs = {n, ñ,X,Y ,ν,R,Z}
and the complete data is given by D = {n, ñ,X,Y ,ν,R,Z, τ 0, τ 1,N
∗}, where
ñ = (n1, . . . , nn). As discussed in (3.1), the joint likelihood of the complete
data requires the specification of three components, P (X | X∗), P (X∗ | R)
and P (Y | X∗,Z,N ∗). The three components can be equivalently expressed
as P (X | X∗) = P (X | τ 0, τ 1), P (X
∗ | R) = P (τ 0, τ 1 | R) and P (Y |
X∗,Z,N ∗) = P (Y | τ 0, τ 1,Z,N
∗), since the information carried by X∗ can be
fully recovered by τ 0 and τ 1. The introduction of the latent vector N
∗ in the
third component can facilitate the development of the MCMC algorithm, and
hence ease the estimation process.





















i=1 ni, θ1 = Σ, Xij· = [xi1(tij) · · · xiq(tij)]
T , τ i·0 = [τi10 · · · τiq0]
T
and τ i·1 = [τi11 · · · τiq1]
T . Let β = (β1, . . . ,βq), Ψ = (Ψ1, . . . ,Ψq) and η =
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(η1, . . . ,ηq), where βk = [βk0 βk1]
T . With the assumption bik = [bik0 bik1]
T ∼

























where θ2 = {β,Ψ,η}, τ ik = [τik0 τik1]
T , and µik = [βk0 + Riηk βk1]
T . To
complete the last piece of the joint likelihood, we further assume that F̃ (t) =















γkτik0 + γkτik1t + Ziδ
}
.
The incorporation of patient-specific trajectory functions in the model of λi(t)
allows patients to have different cure rate structures. Given θ3 = {α,γ, δ} where
γ = (γ1, . . . , γq), and assuming independent censoring, the third component of















N∗i log(Λi(yi)) − log(N
∗
























k=1 γkτik1yi) − exp(−αyi)
exp(
∑q
k=1 γkτik1yi) − 1
,
and f̃i(yi) = αS̃i(yi). Let θ = (θ1,θ2,θ3) denote the set of all the parameters.
The joint likelihood of the complete data is given by
L(θ | D) = L1(θ1)L2(θ2)L3(θ3). (3.13)









Priors for the βk’s, ηk’s, Ψk’s, γk’s, Σ, α and δ are assumed to be independent a
priori. For k = 1, . . . , q, we take normal priors for βk and ηk, and Wishart priors
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for Ψ−1k and Σ
−1. Priors for βk, ηk, Ψk and Σ are motivated by their conjugacy.
We take a normal prior for all the γk’s as well as the vector of survival regression
coefficients δ. Finally, we specify an inverse gamma prior for α. In the analysis
of the IBCSG data, only non-informative priors are considered.
Since we use conjugate priors for βk, ηk, Ψk, k = 1, . . . , q, and Σ, the full
conditionals of these parameters have a closed form and are thus easy to sample.
The conditional posterior distribution for an element of the latent vector N ∗
also has a closed form, and samples are easily obtained from the Poisson density.
For parameters without closed form posteriors, the adaptive rejection algorithm,
proposed by Gilks and Wild (1992), is used to get samples of δ from its log-
concave conditional posterior. An extra Metropolis step is incorporated in the
algorithm by Gilk, Best and Tan (1995), to obtain samples of γ, α and the latent
τ , whose conditional posteriors are not log-concave.
4. Simulation Study
We first conducted a set of simulation studies to evaluate the performance
and computational feasibility of our joint model. This simulation is based on two
longitudinal markers monitored over time, and a survival event in the presence
of cure. Using a total of n = 800 patients, each observed longitudinal marker
xik(tij) was simulated as the sum of the trajectory function x
∗
ik(tij) and the
error term ǫijk, for i = 1, . . . , 800, k = 1, 2 and j = 1, . . . , 6. The trajectory
function was taken as x∗ik(tij) = ηk0 + ηk1tij + ηk2ri + bik0 + bik1tij , where the
ri’s were generated from a standard normal distribution to represent a baseline
covariate in the longitudinal model. Let ηk = [ηk0 ηk1 ηk2]
T , bik = [bik0 bik1]
T
and ǫij· = [ǫij1 ǫij2]
T . We took η1 = [1.0 0.5 1.0]


















in which bik ∼ N2(0,Ψk) and ǫij· ∼ N2(0,Σ). Out of a total of 4,800 longitudinal
observations, 10% of them were randomly chosen to be missing. For the survival




i2(t) + δzi}, for
i = 1, . . . , 800, where zi is a binary baseline covariate with half of the patients
having a 0 and the other half having a 1. We also chose γ1 = −0.3, γ2 = −0.5,
and δ = 1.0. The promotion time was assumed to be an exponential distribution
with a common rate α = 1.0. This set-up leads to a cure rate structure for the
survival time.
We fit two different models to the simulated data. One was a joint model of
longitudinal and survival outcomes (model I) and the other was not (model II).
Model (I) is the model proposed in this paper that accounts for the association
between the longitudinal and survival data, while model II is the model that
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assumes longitudinal and survival data are independent. In other words, we fit
model II by specifying separate models for the longitudinal and survival compo-
nents, which is equivalent to assuming all the γk’s (k = 1, 2) are zero in (3.9).
A total of 100 replications were conducted for this simulation, with 3,000 Gibbs
samples after 500 burn-in for each replication. The convergence of each MCMC
chain was checked by a combination of trace plots and autocorrelations. The pro-
gram was run on a PC cluster configured with 352 CPUs, and the approximate
execution time was 70 hours for 100 replications.
Both models were evaluated in terms of estimation of the longitudinal co-
efficients η12 and η22, and the survival regression coefficient δ for the baseline
covariate. The Deviance Information Criterion (DIC), proposed by Spiegelhal-
ter, Best, Carlin and Van der Linde (2002) was also computed for each model as
a Bayesian measure of fit and complexity for model selection. The smaller the
DIC, the better the fit of the model. Table 1 summarizes the results of the pa-
rameter estimates (posterior means and standard deviations) and DIC statistics,
averaged over replications. The proposed joint model (Model I) appears advan-
tageous against the non-joint model (Model II), in terms of both the parameter
estimates and DIC statistics. When there is a nonzero association between the
longitudinal and survival data, ignoring this association would lead to biased
estimates for important parameters, and thus result in a lack of fit for the data.
Table 1. Posterior summaries and DIC statistics in the simulation.
η12 η22 δ1
Mean SD Mean SD Mean SD DIC
True 1.000 2.000 1.000
Model I 1.007 0.005 2.005 0.005 0.999 0.012 12632.2
Model II 1.019 0.007 2.012 0.005 0.002 0.011 14195.1
We then conducted a series of simulation studies to examine the robustness
of our joint model. Several longitudinal assumptions, such as the independence
and normality of the random effects bik’s, were relaxed. We first generated












and I2 is a 2×2 identity matrix. The proposed joint model was fit. When ρ = 0.1,
the posterior means (with standard deviations in the parenthesis) for η12, η22
and δ, averaged over 100 replications, are 0.994 (0.008), 2.004 (0.009), and 0.995
(0.017), respectively. As the correlation between bi1 and bi2 increases to ρ = 0.2,
the posterior summaries for η12, η22 and δ, averaged over 100 replications, are
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1.007 (0.009), 2.000 (0.008), and 0.997 (0.018), respectively. Given the simulation
setup for η12 = 1.0, η22 = 2.0 and δ = 1.0, our joint model performs quite well in
terms of the estimation of parameters of interest even with moderately correlated
random effects. We then relaxed the normality assumption and simulated the
random effects bi from a multivariate t distribution with mean zero, a = 10
degrees of freedom, and scale matrix (a − 2)Ψ/a to ensure V ar(bi) = Ψ. When
ρ = 0.1, the posterior summaries for η12, η22 and δ are 1.009 (0.010), 2.001
(0.008), and 0.966 (0.016), respectively. The proposed joint model is robust with
respect to the independence and normality assumptions for all random effects.
5. Application to the IBCSG data
We applied the methodology to data from the breast cancer clinical trial.
Before incorporating the patients’ QOL information in the model of DFS, we
first examined the performance of our proposed time-to-event model. Figure 1
shows two superimposed plots for time to breast cancer relapse. The solid line
corresponds to the Kaplan-Meier estimate of survival, while the dashed line cor-
responds to the maximum likelihood estimate of the marginal survival function
based on our model. No covariates were used in constructing the plots. We see
that the two curves are nearly identical and appear to plateau after approxi-
mately 10 years of follow-up. In the proposed survival model, λ(t) decreases over
time, and thus suggests a positive cure fraction in the population.
We then applied our joint model to the data to investigate the relationship
between QOL and DFS. To satisfy the normality assumption for each longitu-
dinal QOL indicator, we transformed the observed QOL to
√
(100 − QOL) (see
Hurny et al. (2000)). With this transformation, the transformed QOL decreased
over time and was scaled between 0 and 10, with smaller values reflecting better
QOL. For each transformed indicator, an individual linear trajectory was consid-
ered to account for patient-specific perception of QOL over time. After visually
inspecting the individual changes of the transformed QOL over time, a linear tra-
jectory function for each indicator appears to be a reasonable choice, especially
based on a maximum of three observations over time. The same baseline co-
variates were incorporated (time after randomization, adjuvant therapy, age and
residency) in the prediction of each QOL assessment. Residency is thought of as a
proxy for “culture”, and thus may affect the patients’ perception of QOL. For the
model of DFS, QOL measures are included as time-varying covariates, and ad-
juvant therapy, age, number of positive nodes and estrogen receptor (ER) status
are included as baseline covariates. The derivation of the joint likelihood as well
as the assumptions are described in Section 3.3. The selections of the baseline
covariates in the longitudinal and survival model were essentially science-driven.
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We use noninformative priors for all the parameters. With G standing
for gamma and W standing for Wishart distribution, the prior specifications
are βk ∼ N2(0, 1000I2), ηk ∼ N6(0, 1000I6), Ψ
−1
k
∼ W2(5, 1000I2), Σ
−1 ∼
W4(7, 1000I4), α
−1 ∼ G(0.01, 0.01), γk ∼ N(0, 1000) and δ ∼ N6(0, 1000I6), for
k = 1, . . . , 4. Four parallel MCMC chains of 25,000 iterations with overdispersed
starting points and with 5,000 iterations as burn-in were run. We visually in-
spected these chains by overlaying their sampled values on a common graph for
each parameter. Each parameter is annotated with the shrinkage factor proposed
by Gelman and Rubin (1992). In order to eliminate autocorrelation among sam-
ples within a sequence, we selected every 10th iteration in each chain. The results
are then presented from the combined chain with 10,000 iterations. All Highest
Posterior Density (HPD) intervals were computed using a Monte Carlo method
proposed by Chen and Shao (1999).
Table 2. Posterior means (with 95% HPD intervals in parentheses) for pa-
rameters in the longitudinal model.
Appetite Coping Mood Physical
Intercept 0.354 0.535 0.434 0.403
( 0.324, 0.370) ( 0.503, 0.550) ( 0.405, 0.448) ( 0.374, 0.417)
Time (in year) -0.044 -0.083 -0.048 -0.012
(-0.060, -0.037) (-0.097, -0.076) (-0.063, -0.040) (-0.025, -0.006)
# Initial cycle -0.005 0.030 0.037 0.013
(-0.033, 0.009) (0.000, 0.044) ( 0.010, 0.050) (-0.013, 0.025)
Reintroduction -0.013 0.007 0.008 -0.021
(-0.041, 0.001) (-0.023, 0.021) (-0.020, 0.021) (-0.047, -0.009)
# Initial cycle 0.006 -0.020 -0.028 0.010
×Reintroduction (-0.034, 0.025) (-0.061, 0.000) (-0.065, -0.001) (-0.025, 0.027)
AGE > 40 0.042 0.022 0.046 0.054
( 0.017, 0.054) (-0.004, 0.033) ( 0.023, 0.057) ( 0.031, 0.065)
Residency: Swiss 0.010 0.037 0.029 0.005
(-0.012, 0.021) ( 0.013, 0.049) ( 0.007, 0.039) (-0.016, 0.014)
Residency: Sweden 0.0167 0.046 0.094 0.059
(-0.008, 0.029) ( 0.020, 0.058) ( 0.070, 0.105) ( 0.036, 0.070)
Table 2 displays posterior summary statistics for parameters related to the
QOL assessments. All transformed indicators for health-related quality of life
decrease over time with HPD intervals excluding 0, suggesting improvement of
QOL after initial surgery. A longer duration of the initial therapy adversely
affects a patient’s mood and coping score, but the reintroduction of a delayed
therapy helps improve a patient’s physical well-being. Younger patients (under
40) have a better quality of life than older patients, and the differences reach
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significance for assessments of appetite, mood and physical well-being. Residency
also plays a role in influencing a patient’s perception of QOL. In general, patients
living in Australia and New Zealand have a better quality of life than patients
living in Switzerland or Sweden. Finally, given the positive estimates for all off-
diagonal elements of Σ (not displayed in Table 2), there is evidence that all QOL
indicators are positively correlated to each other. Better physical well-being, for
instance, leads to a better appetite, mood and coping.
Table 3. Posterior summaries for parameters in DFS model.
Mean HPD interval
Appetite 1.163 (-0.227, 1.825)
Coping score 0.833 ( 0.044, 1.220)
Mood 0.114 (-0.456, 1.298)
Physical well-being 1.087 ( 0.431, 2.501)
# Initial cycle -0.141 (-0.427, -0.002)
Reintroduction -0.528 (-0.816, -0.390)
# Initial cycle×Reintroduction 0.194 (-0.233, 0.397)
AGE > 40 -0.503 (-0.759, -0.378)
# positive nodes > 4 0.930 ( 0.725, 1.027)
ER (1=Positive) -0.423 (-0.637, -0.321)
Table 3 summarizes posterior distributions for parameters related to DFS.
With positive regression coefficients of the transformed QOL measures, patients
having a better quality of life are less likely to have cancer relapse, and the effects
reach significance for coping and physical well-being. All posterior distributions
of the γk’s appear quite symmetric with positive modes. Increased duration of
initial adjuvant chemotherapy and reintroduction of a single course of delayed
chemotherapy are able to delay time to cancer relapse with 95% HPD intervals
excluding zero. Younger patients are more likely to have a relapse than older
patients. Different mechanisms of cancer progression may work for patients under
40 and patients over 40. A positive ER status may reduce the risk of cancer
relapse; however, a greater number of positive nodes may increase the risk of
relapse. Both the effect of ER status and the number of positive nodes are
important effects as indicated by the exclusion of zero in their 95% HPD intervals.
The positive regression coefficients of the transformed QOL indicators (which
decrease over time) in the model of DFS imply a bounded cumulative hazard, and
suggest a nonzero cure fraction in the population. We note that when covariates
are included in the model, each patient has an individual cure fraction. Figure 3
shows the distribution of posterior means of cure rate fractions for all patients.
The mean cure fraction for time to relapse is 0.316 and the standard deviation
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is 0.134. On average, 31.6% of patients are cured and thus are not susceptible to























Figure 3. Boxplot of the posterior means of the cure rates for all patients.
6. Discussion
With more studies being conducted that repeatedly take measures over time
in an effort to evaluate a patient’s health or risk to some event, a joint modeling
approach is essential. We have presented a latent process model for multivariate
repeated measures and a flexible survival model to incorporate the characteristics
of the longitudinal model. Our longitudinal model explicitly acknowledges two
sources of dependence among multidimensional repeated measures and allows
direct inferences on both association over time and over different markers. A
parametric survival model is proposed and is able to accommodate both a zero
and nonzero cure fraction in the population. Aside from the biological motivation,
our time-to-event model is suitable for any type of event time data as long as
the data can be thought of as being generated by a process of latent potential
risks. Thus the model can be useful for analyzing various types of survival data,
including time to relapse, time to death, time to first infection, and so forth.
Future work with this model includes developing methods for hypothesis testing,
model selection and model adequacy assessment.
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